In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression

Journal of Experimental Medicine

Volumn 179, Issue 4, 1994, Pages 1215-1224

  Levitsky, Hyam I ^a   Lazenby, Audrey ^a   Hayashi, Robert J ^b   Pardol, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; GENE TRANSFER; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR REJECTION;

EID: 0028205094     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.179.4.1215     Document Type: Article

References (49)

1. d by cytolytic T cells. Cell 58:293.
2. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC). 254:1643.
3. Pantel, K., G. Schlimok, D. Kutter, G. Schaller, T. Genz, B. Wiebecke, R. Backmann, I. Funke, and G. Riethmuller. 1991. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51:4712.
4. Redondo, M., A. Concha, R. Oldiviela, A. Cueto, A. Gonzalez, F. Garrido, and F. Ruiz-Cabello. 1991. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 51:4948.
5. Tanaka, K., T. Yoshioka, C. Bieberich, and G. Jay. 1988. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu. Rev. Immunol 6:359.
6. Hui, K., F. Grosveld, and H. Festenstein. 1984. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature (Lond.). 311:750.
7. Tanaka, K., E. Gorelik, M. Watanabe, N. Hozumi, and G. Jay. 1988. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol. Cell. Biol 8:1857.
8. Gorelik, E., S. Peppoloni, R. Overton, and R. Herberman. 1985. Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-N′-nitronitrosoguanidine. Cancer Res. 45:5341.
9. Wallich, R., N. Bulbuc, G. Hammerling, S. Katzav, S. Segal, and M. Feldman. 1985. Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature (Lond.). 315:301.
10. Ljunggren, H., and K. Karre. 1990. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today. 11:237.
11. 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J. Immunol. 145:380.
12. Karre, K., H. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature (Lond.). 319: 675.
13. Storkus, W., D. Howell, R. Salter, J. Dawson, and P. Cresswell. 1987. NK susceptibility varies inversely with target cell class I HLA antigen expression. J. Immunol. 138:1657.
14. Ciccone, E., M. Colonna, O. Viale, D. Pende, C. Di Donato, D. Reinarz, A. Amoroso, M. Jeannet, J. Guardiola, A. Moretta, et al. 1990. Susceptibility or resistance to lysis by alloreactive natural killer cells is governed by a gene in the human major histocompatibility complex between BF and HLA-B. Proc. Natl. Acad. Sci. USA. 87:9794.
15. Ciccone, E., D. Pende, O. Viale, C. Di Donato, G. Tripodi, A.-M. Orengo, J. Guardiola, A. Moretta, and L. Moretta. 1992. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J. Exp. Med. 175:709.
16. Ohlen, C., G. Kling, P. Hoglund, M. Hansson, G. Scangos, C. Bieeberich, G. Jay, and K. Karre. 1989. Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice. Science (Wash. DC). 246:666.
17. Bix, M., N. Liao, M. Zijlstra, J. Loring, R. Jaenisch, and D. Raulet. 1991. Rejection of class I MHC deficient haemopoietic cells by irradiated MHC-matched mice. Nature (Lond.). 349:329.
18. Höglund, P., R. Glas, C. Öhlén, H.-G. Ljunggren, and K. Kärre. 1991. Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J. Exp. Med. 174:327.
19. 2-microglobulin transfection to EL-4 mutant cells. J. Exp. Med. 175:843.
20. Lollini, P., C. De Giovanni, B. Del Re, G. Nicoletti, G. Prodi, and P. Nanni. 1987. Interferon-mediated enhancement of metastasis. Are MHC antigens involved? Clin. & Exp. Metastasis. 5:277.
21. Graf, L., P. Kaplan, and S. Silagi. 1984. Efficient DNA-mediated transfer of selectable genes and unselected sequences into differentiated and undifferentiated mouse melanoma clones. Somatic Cell Mol. Genet. 10:139.
22. Fidler, I. 1975. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35:218.
23. Chirgwin, J., A. Pryzbyla, R. MacDonald, and W. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:5294.
24. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 230-235.
25. Graham, E., and A. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 52:457.
26. b gene of C57BL/10 mice. J. Exp. Med. 165:1358.
27. Cǎtipović, B., J. Dal Porto, M. Mage, T.E. Johansen, and J.P. Schneck. 1992. Major histocompatibility complex conformational epitopes are peptide specific. J. Exp. Med. 176:1611.
28. Blok, R., D. Margulies, L. Pease, R. Ribaudo, J. Schneck, and J. McCluskey. 1992. CD8 expression alters the fine specificity of an allo-reactive MHC class I specific T hybridoma. Int. Immunol. 4:455.
29. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R.C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:3539.
30. Fearon, E.R., D.M. Pardoll, T. Itaya, P. Golumbek, H.I. Levitsky, J.W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:397.
31. Dialynas, D.M., Z.S. Quan, K.A. Wall, A. Pierres, J. Quintans, M.R. Loken, M. Pierres, and F. Fitch. 1983. Characterization of the murine T cell surface molecule, designated L3T4, identified by the monoclonal antibody GK1.5. J. Immunol. 131:2445.
32. Sarmiento, M., A. Glasebrook, and F. Fitch. 1980. IgG and IgM antibodies reactive with different determinants on the molecular complex bearing Lyt-2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol 125:2665.
33. - mouse: a model to study differentiation of murine NK cells. J. Immunol. 137:3742.
34. Silagi, S., D. Beju, J. Wrathall, and E. Deharven. 1972. Tumorigenicity, immunogenicity, and virus production in mouse melanoma cells treated with 5-bromodexyuridine. Proc. Natl. Acad. Sci. USA. 69:3443.
35. Lollini, P., D. De Giovanni, G. Nicoletti, A. Bontadini, P. Tazzari, L. Landuzzi, K. Scotlandi, and P. Nanni. 1990. Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. Clin. & Exp. Metastasis. 8:215.
36. Golumbek, P.T., A.J. Lazenby, H.I. Levitsky, L.M. Jaffee, H. Karasuyama, M. Baker, and D.M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Wash. DC). 254:713.
37. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47:187.
38. Cantor, H., and E. Boyse. 1975. Functional subclass of T-lymphocytes bearing different Ly antigens. J. Exp. Med. 141:1390.
39. Zinkernagel, R., G. Callahan, A. Althage, S. Cooper, J. Streilein, and J. Klein. 1978. The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T cell help. J. Exp. Med. 147:897.
40. von Boehmer, H., and W. Haas. 1979. Distinct Ir genes for helper and killer cells in the cytotoxic response to H-Y antigen. J. Exp. Med. 150:1134.
41. Keene, J., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768.
42. Trinchieri, G., M. Matsumoto-Kobayashi, S. Clark, J. Sheehra, L. London, and B. Perussia. 1984. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 160:1147.
43. Trinchieri, G., and D. Santoli. 1978. Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J. Exp. Med. 147:1314.
44. Bennett, M. 1987. Biology and genetics of hybrid resistance. Adv. Immunol. 41:333.
45. Yu, Y., V. Kumar, and M. Bennett. 1992. Murine natural killer cells and marrow graft rejection. Annu. Rev. Immunol. 10:189.
46. Cudkowicz, G. 1975. Rejection of bone marrow allografts by irradiated athymic nude mice. Proc. Am. Assoc. Cancer Res. 16:170.
47. Rembecki, R., M. Bennett, V. Kumar, and C. David. 1987. Expression of hemopoietic histocompatibility antigen (Hh-1) in the H-2D/H-2L recombinant strain B10.RQDB. Fed. Proc. 46:1361.
48. b bone marrow grafts. J. Exp. Med. 170:191.
49. Karre, K., H. Ljunggren, G. Piontek, R. Kiessling, G. Klein, K. Taniguchi, and A. Gronberg. 1984. Activation of cell mediated immunity by absence or deleted expression of normal cellular gene products, i.e., by "no self" rather than "non self"? Immunobiology. 67:43.